



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/706,321
Filing Date	November 12, 2003
First Named Inventor	Michael Wandell
Group Art Unit	1743
Examiner Name	Jeffrey R. Snay
Attorney Docket Number	006405.00029

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/LR/ ↓		US- 5,978,466	11/02/1999	Quattrocchi	
		US- 6,014,438	01/11/2000	Quattrocchi	
		US- 6,016,345	01/18/2000	Quattrocchi	
		US- 6,226,378	05/01/2001	Quattrocchi	
		US- 5,435,970	07/25/1995	Mamenta et al.	
		US- 6,040,135	03/21/2000	Tyrrell	
		US- 4,839,296	06/13/1989	Kennedy et al.	
		US- 6,187,531	02/13/2001	Tyrrell	
		US- 5,935,775	08/10/1999	Savjani	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/LR/ ↓		EP 0 503 356 B1	10-30-1996	Fresenius AG		
		WO 00/44930	08-03-2000	Abbott Lab		
		EP 0 419 196 A2	03-27-1991	Nova Biomedical Corp.		

Examiner
Signature

/Lore Ramillano/

Date
Considered

12/09/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/706,321
Filing Date	November 12, 2003
First Named Inventor	Michael Wandell
Group Art Unit	1743
Examiner Name	Jeffrey R. Snay
Attorney Docket Number	006405.00029

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/LR/		FELIX WROBLEWSKI and JOHN S. LADUE; Serum Glutamic Pyruvate Transaminase in Cardiac and Hepatic Disease; Proceedings of the Society for Experimental Biology and Medicine; January - April, 1956, Volume 91, New York	
		MICHAEL MCGOWAN, JOSEPH D. ARTISS, DONALD R. STRANDBERGH, and BENNIE ZAK; A peroxidase-Coupled Method for the Colorimetric Determination of Serum Triglycerides; Journal of the American Association for Clinical Chemistry; Volume 29, Number 1, January 1983	
		CHARLES C. ALLAIN, LUCY S. POON, CICELY S.G. CHAN, W. RICHMOND, AND PAUL C. FU; Enzymatic Determination of Total Serum Cholesterol; Clinical Chemistry, Volume 20, No. 4, 1974	
		CALLUM G. FRASER, STEVEN T. CUMMINGS, STEPHEN P. WILKINSON, RONALD G. NEVILLE, JAMES D. E. KNOX, OLGA HO, and RONALD S. MacWalter; Biological Variability of 26 Clinical Chemistry Analytes in Elderly People; Clinical Chemistry, Volume 35, No. 5, 1989	
		M.D. PENNEY and G. WALTERS; Are osmolality measurements clinically useful?; Journals of Clinical Biochemistry; Volume 24, Part 6, November 1987	
		BRADLEY P. CARLIN and THOMAS A. LOUIS; Bayes and Empirical Bayes Methods for Data Analysis; Texts in Statistical Science, 2000, Pages 17 - 46, Second Edition,	
		NADER RIFAI and G. RUSSELL WARNICK; Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins; American Association of Clinical Chemistry, 1994, Pages 65 - 107	
		RAVEL, RICHARD; Clinical Laboratory Medicine; Sixth Edition, 1995, Pages 171-172, 405-413 and 417-420	
		ERHARDT, JUERGEN G et al.; Combined measurement of retinol and soluble transferring receptor (sTfR) in a single dried blood spot (DBS) stored at room temperature; Faseb Journal; vol. 16, no. 4, March 20, 2002, pages A247-A248, XP009019440; Annual Meeting of the Professional Research Scientists on Experimental Biology; New Orleans, Louisiana, USA; April 20-24, 2002	
		ERHARDT, JUERGEN G et al.; Rapid and Simple Measurement of Retinol in Human Dried Whole Blood Spots; Journal of Nutrition; vol. 132, no. 2, February 2002; pages 318-321, XP002258787	
↓		O'BRIEN J M et al.; Detection of Hepatitis C Antibody with At-Home Collection Kits Using an Innovative Laboratory Algorithm; Infectious Diseases in Clinical Practice; 2001 USA; vol. 10, no. 9, pages 474-480; XP00115589	

Examiner
Signature

/Lore Ramillano/

Date
Considered

12/09/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10706321
Filing Date		2003-11-12
First Named Inventor	Michael Wandell	
Art Unit	1743	
Examiner Name	Jeffrey R. Snay	
Attorney Docket Number	006405.00029	

/LR/	1	PALARDY J ET AL., "Blood Glucose Measurements During Symptomatic Episodes in Patients With Suspected Postprandial Hypoglycemia", New England Journal of Medicine, November 23, 1989, Pages 1421-1425, Vol. 321, No. 21, Massachusetts Medial Society, USA [XP009061174]	<input type="checkbox"/>
/LR/	2	HOWE, CHRISTOPHER J ET AL., "Use of filter paper for sample collection and transport in steroid pharmacology", Clinical Chemistry, 1997, Pages 1408-1415, Vol. 43, No. 8 Part 1. [XP-002366288]	<input type="checkbox"/>
/LR/	3	International Search Report for PCT/US2005/040051	<input type="checkbox"/>
/LR/	4	Written Opinion for PCT/US2005/040051	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Lore Ramillano/	Date Considered	12/09/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/706,321
Filing Date	November 12, 2003
First Named Inventor	Michael Wandell
Art Unit	1743
Examiner Name	Lore Janet Ramillano
Attorney Docket Number	36664.00.0013

Sheet	1	of	1
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Lore Ramillano/	Date Considered	12/09/2007
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.